PolyPid Ltd. (PYPD)Healthcare | Biotechnology | Petah Tikva, Israel | NasdaqCM
4.90 USD
+0.07
(1.449%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 5:12 a.m. EDT
The investment case for PolyPid is currently broken by a catastrophic multi-year decline and deteriorating fundamentals. The stock has lost nearly 99% of its value over the last five years, with every single year showing negative returns, signaling a persistent failure to execute or deliver value. While the company boasts a 'strong buy' analyst recommendation and promising Phase 3 clinical data, these positives are completely overshadowed by the reality of burning cash, negative returns on equity, and a balance sheet that cannot sustain the current burn rate without further dilution. The market has correctly priced this as a value trap; the low price is not a margin of safety but a reflection of the business's inability to generate profit. With no dividend to provide income and a statistical forecast predicting further downside, the risk/reward profile is severely skewed against the buyer. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.051653 |
| MSTL | 0.055197 |
| AutoETS | 0.062864 |
| AutoARIMA | 0.062864 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 0.96 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.222 |
| Excess Kurtosis | -0.68 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 29.176 |
| Market Cap | 99,527,656 |
| Forward P/E | -3.99 |
| Beta | 1.38 |
| Website | https://www.polypid.com |
As of Oct. 10, 2026, 5:12 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest dominates across all expirations, with significant concentration in out-of-the-money strikes (e.g., $2.50) suggesting a fear of a deeper collapse. Call activity is minimal and heavily skewed toward out-of-the-money strikes, indicating a lack of conviction in a recovery. Implied volatility is elevated relative to deep OTM puts, reflecting a 'crash' premium rather than a rally expectation.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.4984709 |
| Address1 | 18 Hasivim Street |
| All Time High | 583.5 |
| All Time Low | 2.3 |
| Ask | 5.15 |
| Ask Size | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 104,330 |
| Average Daily Volume3 Month | 167,675 |
| Average Volume | 167,675 |
| Average Volume10Days | 104,330 |
| Beta | 1.379 |
| Bid | 3.6 |
| Bid Size | 2 |
| Book Value | 0.265 |
| City | Petah Tikva |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.9 |
| Current Ratio | 1.346 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 4.97 |
| Day Low | 4.66 |
| Debt To Equity | 29.176 |
| Display Name | PolyPid |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,537,800 |
| Earnings Call Timestamp Start | 1,786,537,800 |
| Earnings Timestamp | 1,786,537,800 |
| Earnings Timestamp End | 1,794,400,200 |
| Earnings Timestamp Start | 1,794,400,200 |
| Ebitda | -30,118,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.139 |
| Enterprise Value | 94,536,656 |
| Eps Current Year | -0.89 |
| Eps Forward | -1.2275 |
| Eps Trailing Twelve Months | -1.44 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.0915 |
| Fifty Day Average Change | -0.19149971 |
| Fifty Day Average Change Percent | -0.03761165 |
| Fifty Two Week Change Percent | 49.84709 |
| Fifty Two Week High | 5.73 |
| Fifty Two Week High Change | -0.8299999 |
| Fifty Two Week High Change Percent | -0.14485164 |
| Fifty Two Week Low | 3.1 |
| Fifty Two Week Low Change | 1.8000002 |
| Fifty Two Week Low Change Percent | 0.58064526 |
| Fifty Two Week Range | 3.1 - 5.73 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,593,178,200,000 |
| Float Shares | 12,163,295 |
| Forward Eps | -1.2275 |
| Forward P E | -3.9918535 |
| Free Cashflow | -17,364,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 69 |
| Fullday Change | -0.01999998 |
| Fullday Change Percent | -0.40816286 |
| Fullday Price | 4.88 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12336001 |
| Held Percent Institutions | 0.34576 |
| Implied Shares Outstanding | 20,311,766 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-06-26 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,695,254,400 |
| Last Split Factor | 1:30 |
| Long Business Summary | PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. |
| Long Name | PolyPid Ltd. |
| Market | us_market |
| Market Cap | 99,527,656 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_49223295 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -31,501,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 107,043,006 |
| Number Of Analyst Opinions | 4 |
| Open | 4.7 |
| Operating Cashflow | -29,003,000 |
| Operating Margins | 0.0 |
| Phone | 972 7 4719 5700 |
| Pre Market Change | -0.01999998 |
| Pre Market Change Percent | -0.40816286 |
| Pre Market Price | 4.88 |
| Pre Market Time | 1,792,153,935 |
| Previous Close | 4.83 |
| Price Eps Current Year | -5.505618 |
| Price Hint | 4 |
| Price To Book | 18.490568 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.994 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | 0.0700002 |
| Regular Market Change Percent | 1.44928 |
| Regular Market Day High | 4.97 |
| Regular Market Day Low | 4.66 |
| Regular Market Day Range | 4.66 - 4.97 |
| Regular Market Open | 4.7 |
| Regular Market Previous Close | 4.83 |
| Regular Market Price | 4.9 |
| Regular Market Time | 1,792,094,400 |
| Regular Market Volume | 120,507 |
| Return On Assets | -0.74625 |
| Return On Equity | -2.4359 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 20,311,766 |
| Shares Percent Shares Out | 0.0062 |
| Shares Short | 126,220 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 194,996 |
| Short Name | PolyPid Ltd. |
| Short Percent Of Float | 0.0083 |
| Short Ratio | 1.37 |
| Source Interval | 15 |
| Symbol | PYPD |
| Target High Price | 14.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 11.75 |
| Target Median Price | 12.5 |
| Total Cash | 6,563,000 |
| Total Cash Per Share | 0.323 |
| Total Debt | 1,572,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.684725 |
| Two Hundred Day Average Change | 0.21527529 |
| Two Hundred Day Average Change Percent | 0.0459526 |
| Type Disp | Equity |
| Volume | 120,507 |
| Website | https://www.polypid.com |
| Zip | 4,959,376 |